ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search
  • 2018 American Transplant Congress

    CFZ533, a New Anti-CD40 mAB Demonstrates Comparable Efficacy and Better Renal Function versus Tacrolimus in De-Novo CNI-Free Kidney Transplantation

    B. Nashan,1 H. Tedesco,1 M. van den Hoogen,1 S. Berger,1 D. Cibrik,1 S. Mulgaonkar,1 D. Leeser,1 R. Alloway,1 A. Patel,1 J. Pratschke,1 C. Sommerer,1 A. Wiseman,1 A. van Zuilen,1 U. Laessing,2 J. Rush,2 B. Haraldsson,2 O. Witzke.1

    1CFZ533 Study Group, Basel, Switzerland; 2Novartis Pharma, Basel, Switzerland.

    Purpose: To assess the potential of CFZ533 as primary immunosuppressant in a calcineurin(CNI)-free regimen in de novo kidney transplant (KTx) patients(pts).Method: CFZ533 is a new,…
  • 2018 American Transplant Congress

    Donor-Specific Antibody Mediates Chronic, but Not Acute, Kidney Allograft Rejection in the Absence of Natural Killer Cells

    T. Yagisawa, N. Dvorina, A. Valujskikh, W. Baldwin 3rd, R. Fairchild.

    Immunology and Glickman Urological Institute, Cleveland Clinic, Cleveland, OH.

    The incidence of antibody-mediated kidney graft rejection continues to increase. We previously reported that dysregulated donor-specific antibody (DSA) responses were induced in B6.CCR5-/- mice transplanted…
  • 2018 American Transplant Congress

    Impact of Rapid Discontinuation of Prednisone on Kidney Transplant Outcomes in At-Risk Subpopulations: An OPTN/SRTR Analysis

    D. Vock,1 A. Matas.2

    1Public Health, U of MN, Mpls, MN; 2Surgery, U of MN, Mpls, MN.

    Objective: Successful RDP (rapid discontinuation of prednisone <1 week post-tx) after kidney transplant (KTx) has been reported for low-risk populations. We studied the impact of…
  • 2018 American Transplant Congress

    Early Considerations for Deceased Donor Chains

    A. Toll,1 R. Leishman,1 V. Casingal,2 M. Aeder,3 T. Sandholm,4 N. Turgeon.5

    1UNOS, Richmond, VA; 2Carolinas HeathCare Sys, Charlotte, NC; 3Univ Hosp Med Ctr, Cleveland, OH; 4Carnegie Mellon Univ, Pittsburgh, PA; 5Emory Univ, Atlanta, GA.

    Background: The potential use of deceased kidney donors (DDs) to initiate kidney paired donation (KPD) chains (DD chains) has been of interest to the transplant…
  • 2018 American Transplant Congress

    Comparison of Recipients with Early and Late Presenting Polyomavirus Nephropathy (PVN) with Regard to Histological Findings and Graft Survival: What is the Influence of CD4/CD8 Ratio on the Presenting Time of PVN

    B. Ozdemir,1 S. Ayva,1 A. Terzi,1 A. Ok Atilgan,1 E. Akcay,1 E. Ayvazoglu Soy,2 F. Ozdemir,3 M. Haberal.2

    1Pathology, Baskent University, Ankara, Turkey; 2Transplantation, Baskent University, Ankara, Turkey; 3Nephrology, Baskent University, Ankara, Turkey.

    Introduction: PVN is a common complication occurring around 12 mo after renal transplant (RT). We aimed to explore the differences between early and late-onset PVN…
  • 2018 American Transplant Congress

    Pancreas Transplant Recipients with End-Stage Renal Disease Benefit from Kidney Transplantation

    Y. Tang, Z. Zhu, S. Huang, Z. Zhang, W. Ju, Z. Guo, X. He, G. Chen.

    Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.

    Background: End-stage renal disease (ESRD) has been shown after pancreas transplant alone (PTA), however, the benefit of kidney transplantation (KT) in PTA recipients with ESRD…
  • 2018 American Transplant Congress

    Shared HLA Specificities between the Blood and Transplant Donor Increases the Risk of De Novo DSA Development Following Blood Transfusion in Transplant Recipients

    S. Hassan,1 F. Regan,2 C. Brown,3 A. Harmer,2 N. Anderson,2 E. Santos,4 P. Brookes,4 D. Taube,1 M. Willicombe.1

    1Renal and Transplant Centre, Imperial College Healthcare NHS Trust, London, United Kingdom; 2Haematology, Imperial College Healthcare NHS Trust, London, United Kingdom; 3Histocompatibility and Immunogenetics, NHS Blood and Transplant, London, United Kingdom; 4Histocompatibility and Immunogenetics, Imperial College Healthcare NHS Trust, London, United Kingdom.

    Introduction: Blood transfusions post-transplant have been shown to be associated with the development of de novo DSA and inferior allograft outcomes. The mechanisms behind this…
  • 2018 American Transplant Congress

    HLA Eplet Mismatch and Donor Specific Antibodies in Kidney Transplantation

    S. Wan,1,2 S. Angel de Wilde,2 B. Rosales,2 S. Chadban,1,2 K. Wyburn.1,2

    1Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia; 2Sydney Medical School, University of Sydney, Sydney, Australia.

    BACKGROUND: Although HLA matching improves graft survival in kidney transplant recipients (KTx), eplet mismatches provide higher resolution information, and could better predict the development of…
  • 2018 American Transplant Congress

    Emergence of a Costimulation-Susceptible T Cell Repertoire Post-Alemtuzumab Induction

    Q. Gao,1 A. Mehta,2 A. Guasch,2 L. Stempora,1 A. Kirk,1 H. Xu.1

    1Department of Surgery, Duke University Medical Center, Durham, NC; 2Emory Transplant Center, Emory University School of Medicine, Atlanta, GA.

    Kidney transplant patients treated with belatacept-based regimens without depletional induction have higher rates of costimulation blockade resistant rejection (CoBRR). In contrast, belatacept effectively prevents rejection…
  • 2018 American Transplant Congress

    Improving Prognostication amongst Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma: An International, 16-Center Study to Validate and Recalibrate HALTHCC

    D. Firl,1 K. Sasaki,1 S. Kimura,2 W. Dumronggittigule,3 A. Gorgen,4 J. Lerut,5 M. Rossi,6 U. Cillo,7 A. Viveiros,8 E. Tsochatzis,9 G. Otto,10 G. Ettorre,11 G. Tisone,12 M. Vivarelli,13 S. Agnes,14 J. Markmann,2 T. Ikegami,15 T. Kaido,16 G. Sapisochin,4 V. Agopian,3 Q. Lai,5,6 F. Aucejo.1

    1CCF, Cleveland; 2MGH, Boston; 3UCLA, LA; 4UHN, Toronto, Canada; 5SLH, Louvain, Belgium; 6UH, Rome, Italy; 7UP, Padua, Italy; 8MUI, Innsbruck, Austria; 9UCL, London, United Kingdom; 10UM, Mainz, Germany; 11SCH, Rome, Italy; 12TVU, Rome, Italy; 13AOU, Torrette Ancona, Italy; 14AGH, Rome, Italy; 15KU, Kyoto, Japan; 16KU, Kyushu, Japan.

    Objective: Prognosticating outcomes in liver transplant (LT) for hepatocellular carcinoma (HCC) continues to challenge the field. Whereas adoption of the binary Milan Criteria (MC) generalized…
  • « Previous Page
  • 1
  • …
  • 193
  • 194
  • 195
  • 196
  • 197
  • …
  • 211
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences